University of Washington
Development of Protein-targeted Aptamers for Cancer Therapeutics
Abstract
dc:description.abstractAptamers are single-stranded DNA or RNA molecules capable of recognizing and tightly binding to a variety of targets with high specificity. Treatment of brain and CNS disorders remains the holy grail of drug delivery due to the obstacle imposed by the blood-brain barrier (BBB). Bearing various advantages such as small size, low immunogenicity, and ease of large-scale synthesis at affordable costs, aptamers are an emerging field of novel cancer therapeutics that demonstrate the potential for BBB crossing. Here, we aimed to develop aptamer-based targeting vehicles utilizing the endogenous iron-loading pathway involving the transferrin receptor (TfR, or CD71) and its ligand, transferrin (Tf). We demonstrated our expansive effort in the discovery of Tf binding aptamers via protein-SELEX and the characterization, cross-reactivity, and preliminary data for future applications of a CD71 binding aptamer, tJBA.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Zhou, Yunshi
- Advisor dc:contributor.advisor
-
- Pun, Suzie
Subjects
dc:subject × 3Rights
dc:rights- Statement dc:rights
-
- CC BY
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- http://hdl.handle.net/1773/45836